EN DE
Watch Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock TRY 5.23, price TRY 5.51, that is 5.1% below the price, quality 31 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TR · ISIN TREANGN00028

AT Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret logo Thin data Oct 29, 2026

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret

ANGEN · IS
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value 5.23 TRY · Fairly valued (−5.1%)
Expensive Growth (revenue 3y +40.1 %/yr in TRY)
Quality 31/100
Loss-making · -34.6% net margin (TTM)
Negative free cash flow
Trails peers (3/11)
Narrow moat 10/100 · thin data
Thin data
Watch Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

23.13 TRY 5.51 TRY Fair Value 5.23 TRY Oct 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.

How to read this chart

60‑month range 5.51 TRY – 23.13 TRY · fair‑value band 3.73 TRY – 6.74 TRY · the 5.51 TRY price screens above the 5.23 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.

Follow Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret in your weekly email

Every Wednesday you see whether Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, rapid antigen test kits, and automated nucleic acid (NA) extraction instruments in Turkey.

Show moreShow less

It offers microbiology, genetic disorder, multiplex panel, drug resistance sequencing, food testing kits, as well as sample collection and transport; and full automation, manual magnetic bead NA extraction, and automated NA extraction instrument kits.

The company also provides products for diseases, such as hepatitis, herpes simplex virus, human papillomavirus, COVID-19, respiratory infections, monkeypox, human immunodeficiency virus, west nile virus, meningitis, brucella, crimean-congo hemorrhagic fever, sexually transmitted diseases, epstein-barr virus, tuberculosis, JC and BK polyomaviruses, cytomegalovirus, parvovirus B19, toxoplasmosis, ureaplasma, torque teno virus, factor V leiden mutation, factor II prothrombin mutation, methylenetetrahydrofolate reductase, influenza, and respiratory syncytial virus diseases.

In addition, it is involved in installation of robots, developing software; and designing of devices for research of real-time PCR. Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. was founded in 2010 and is headquartered in Istanbul, Turkey.

Stock analysis

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) currently trades at 5.51 TRY, while our model-based Fair Value estimate is 5.23 TRY, so the stock looks roughly fairly valued today (gap 5.4%).

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 3.73 TRY (bear) to 6.74 TRY (bull), the price of 5.51 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret reported revenue of 740M TRY in FY2025 versus 410M TRY in FY2021, a compound +15.9%/yr. Reported net income was −313M TRY in FY2025.

Key figures

Market cap 1.2B TRY (≈ $24.3M) Micro · P/S ratio 1.72 · EPS (TTM) −1.40 TRY · Net margin −34.6% · Return on equity −15.0% · Return on assets (EBIT) 9.0% · Operating margin −0.4% · Revenue (TTM) 747M TRY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −5%, ANGEN screens cheaper than that median.

Fair Value models

Bear 3.73 TRY Fair Value 5.23 TRY Bull 6.74 TRY
Price 5.51 TRY · Downside -5.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA 3.73 TRY 5.23 TRY 6.74 TRY 67
NCAV (Graham) 0.3000 TRY 0.4500 TRY 0.5600 TRY 55
All 2 models by family
Multiples
EV/EBITDA 3.73 TRY 5.23 TRY 6.74 TRY 67
Asset-Based
NCAV (Graham) 0.3000 TRY 0.4500 TRY 0.5600 TRY 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
81.2% (2020) → −7.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ANGEN, get fair value alerts →

Compare Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 319 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −5.1% · Above median
Profitability
Return on assets −13.2% · Bottom 25%
Net margin (12 months) −34.6% · Bottom 25%
Operating margin (12 months) −0.4% · Below median
Growth and dividend
Revenue growth (quarter YoY) 3.1% · Below median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.70× · Cheapest 25%
P/S (12 months) 1.62× · Cheaper than median
EV/EBITDA 80.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)27 · sector 8
FUTURE (revenue growth)16 · sector 36
PAST (return on equity)0 · sector 16
HEALTH (low debt)95 · sector 98
DIVIDEND (yield)0 · sector 36

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $291.86 $321.05 +10% vs ANGEN
Boston Scientific Corporation BSX $41.98 $46.18 +10% vs ANGEN
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥181.75 ¥199.93 +10% vs ANGEN
DexCom, Inc DXCM $82.29 $90.52 +10% vs ANGEN
GE HealthCare Technologies Inc GEHC $76.57 $69.92 −9% vs ANGEN
Edwards Lifesciences Corporation EW $92.01 $82.04 −11% vs ANGEN
Siemens Healthineers AG SHL €42.89 €35.21 −18% vs ANGEN
Abbott Laboratories, ABT $106.20 $75.28 −29% vs ANGEN
Medtronic plc MDT $96.54 $65.61 −32% vs ANGEN
Koninklijke Philips N.V PHIA €24.24 €15.23 −37% vs ANGEN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret · Fair Value
5.23 TRY −5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret Fair Value". https://www.fairvalue-calculator.com/stock/ANGEN

Frequently asked questions

Is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 5.23 TRY versus a price of 5.51 TRY, about 5% lower (fairly valued).
What is the fair value of ANGEN?
Our model-based fair value for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 5.23 TRY (as of Oct 29, 2026), built from audited fundamentals. The current price: 5.51 TRY.
What is the quality score of ANGEN?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Our model-based price target is the fair value of 5.23 TRY (as of Oct 29, 2026) from 2 valuation models. Cautious scenario 3.73 TRY, optimistic scenario 6.74 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock forecast for 2026?
Our models put fair value at 5.23 TRY, about 5% lower versus a price of 5.51 TRY (fairly valued). Cautious scenario 3.73 TRY, optimistic scenario 6.74 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret reported trailing-twelve-month revenue of about 747M TRY (latest available figure, as of Oct 29, 2026).
What is the intrinsic value of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret it is 5.23 TRY per share (as of Oct 29, 2026), against a price of 5.51 TRY. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock overvalued or undervalued in 2026?
As of Oct 29, 2026, ANGEN trades above its calculated fair value: price 5.51 TRY, fair value 5.23 TRY, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANGEN?
No. The price is what the market pays today (5.51 TRY); the fair value is what the company's own numbers justify (5.23 TRY). For Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret the two are 0.2800 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret worth?
The market values Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret at about 1.2B TRY (market capitalisation, as of Oct 29, 2026). Per share that is 5.51 TRY; our models calculate a fair value of 5.23 TRY per share.
What do the bullish and bearish scenarios say about ANGEN?
Our models span a range for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret: cautious scenario 3.73 TRY, base 5.23 TRY, optimistic 6.74 TRY per share (as of Oct 29, 2026, price 5.51 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Balance-sheet figures for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (as of Oct 29, 2026): return on equity −15.0%, debt of 0.11 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is ANGEN from its 52-week high?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret trades at 5.51 TRY, about 63% below its 52-week high of 14.70 TRY and at the low of 5.51 TRY (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of 5.23 TRY is for.
Which stocks are comparable to Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock attractive at the current price?
The data as of Oct 29, 2026: price 5.51 TRY, calculated fair value 5.23 TRY (−5%), Quality Score 31/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANGEN calculated?
We run Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5.23 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The closing price on Oct 30, 2026 was 5.51 TRY. Our model-based fair value is 5.23 TRY, about 5% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (3.73 TRY to 6.74 TRY) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret

How large is the market capitalisation of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The market capitalisation of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 1.2B TRY (≈ $24.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The price-to-sales ratio of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 1.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Earnings per share at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret are −1.40 TRY. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The net margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −34.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The return on equity (ROE) of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −15.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
On an EBIT basis the return on assets of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The operating margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Revenue at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is growing +3.1% versus a year earlier (3y avg +40.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Earnings per share at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret are growing −93.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) generate?
The free cash flow of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −186M TRY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) carry?
The net debt of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 175M TRY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret in the live analysis

One click puts Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.